Independent Real-World Study Demonstrates Significant Improvements for Adults who have SMA Type 3, Treated with Nusinersen

06 October 2020

In response to a request from SMA Europe, Biogen has sent this community update which includes the observation that the most relevant treatment effect was seen in those with SMA Type 3 who were unable to walk without assistance at the start of treatment. 

We hope to know soon when and how NICE’s evidence review for this group, currently excluded from treatment in England, will be conducted. 

The update also includes outcomes for a small group who have SMA Type 2.

Read the community update